At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

A team at Scripps Research has created a microchip that can rapidly reveal how a person's antibodies respond to viruses using only a drop of blood. This game-changing technology, called mEM, condenses ...

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

A new microchip invented by Scripps Research scientists can reveal how a person's antibodies interact with viruses—using just ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

A local cancer survivor, Robert Dames, has released a new book titled "Cancer - What Now" to assist others in navigating the ...

These antibodies have variable regions specific for surface molecules on B cells, and a constant region with an inserted antigen.

Circulate Health, a Seattle health longevity startup, today announced $12 million in seed funding to expand its plasma ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...